Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy

被引：29

作者：

Ahirwar, Dinesh K. ^{[1
]}

Mandhani, Anil ^{[1
]}

Dharaskar, Anand ^{[1
]}

Kesarwani, Pravin ^{[1
]}

Mittal, Rama D. ^{[1
]}

机构：

[1] SGPGIMS, Dept Urol & Renal Transplantat, Lucknow 226014, Uttar Pradesh, India

来源：

BJU INTERNATIONAL | 2009年 / 104卷 / 06期

关键词：

bacille Calmette-Guerin; polymerase chain reaction (PCR); polymorphism; recurrence; TNF-alpha; bladder cancer; BCG IMMUNOTHERAPY; ALLELE; TNF; INFLAMMATION; POPULATION; RECURRENCE; MECHANISMS; CARCINOMA; PROMOTER; JAPANESE;

D O I：

10.1111/j.1464-410X.2009.08549.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

100201 [内科学]; 100221 [泌尿外科学];

摘要：

OBJECTIVE To investigate the association of tumour necrosis factor-alpha gene (TNF-alpha) polymorphisms T-1031C, C-863A, and C-857T with bladder cancer risk and recurrence after bacille Calmette-Guerin (BCG) immunotherapy, as TNF-alpha regulates inflammatory process influencing bladder cancer susceptibility and outcome of BCG immunotherapy. PATIENTS AND METHODS In all, 220 patients with bladder cancer and 206 controls were recruited. Genotyping was done using allele specific-polymerase chain reaction. RESULTS A T-1031C, CC genotype and haplotype -1031C/-863C/-857T showed enhanced susceptibility to bladder cancer, with an odds ratio (OR) of 2.23 and 95% confidence interval (CI) of 1.17-4.26; and an OR of 6.05 and 95%CI of 2.46-14.90, respectively. A T-1031C, CC genotype had a reduced risk of recurrence after BCG treatment (hazard ratio 0.38, 95%CI 0.14-0.98). CONCLUSION The present data suggests that T-1031C (CC) genotype and C/C/T haplotype may confer risk for bladder cancer, moreover T-1031C (CC) decreased the risk of recurrence after BCG immunotherapy.

引用

页码：867 / 873

页数：7

共 26 条

[1]

Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer [J].

Ahirwar, Dinesh ;

Kesarwani, Pravin ;

Manchanda, Parmeet Kaur ;

Mandhani, Anil ;

Mittal, Rama Devi .

CANCER GENETICS AND CYTOGENETICS, 2008, 184 (01) :1-8

[2]

BCG immunotherapy of bladder cancer: 20 years on [J].

Alexandroff, AB ;

Jackson, AM ;

O'Donnell, MA ;

James, K .

LANCET, 1999, 353 (9165) :1689-1694

[3]

[Anonymous], 1997, J CLIN PATHOL

[4]

Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy [J].

Basturk, Bilkay ;

Yavascaoglu, Ismet ;

Oral, Barbaros ;

Goral, Guher ;

Oktay, B. .

CYTOKINE, 2006, 35 (1-2) :1-5

[5]

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer [J].

Böhle, A ;

Brandau, S .

JOURNAL OF UROLOGY, 2003, 170 (03) :964-969

[6]

INDUCTION OF URINARY INTERLEUKIN-1 (IL-1), IL-2, IL-6, AND TUMOR-NECROSIS-FACTOR DURING INTRAVESICAL IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER [J].

DEBOER, EC ;

DEJONG, WH ;

STEERENBERG, PA ;

AARDEN, LA ;

TETTEROO, E ;

DEGROOT, ER ;

VANDERMEIJDEN, APM ;

VEGT, PDJ ;

DEBRUYNE, FMJ ;

RUITENBERG, EJ .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (05) :306-312

[7]

CYTOKINE PRODUCTION BY THE HUMAN BLADDER-CARCINOMA CELL-LINE T24 IN THE PRESENCE OF BACILLUS-CALMETTE-GUERIN (BCG) [J].

DEREIJKE, TM ;

VOS, PCN ;

DEBOER, EC ;

BEVERS, RFM ;

KEIZER, WHD ;

KURTH, KH ;

SCHAMHART, DHJ .

UROLOGICAL RESEARCH, 1993, 21 (05) :349-352

[8]

EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921

[9]

Increased frequency of the uncommon tumor necrosis factor-857T allele in British and Dutch patients with sarcoidosis [J].

Grutters, JC ;

Sato, H ;

Pantelidis, P ;

Lagan, AL ;

McGrath, DS ;

Lammers, JWJ ;

van den Bosch, JMM ;

Wells, AU ;

du Bois, RM ;

Welsh, KI .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (08) :1119-1124

[10]

Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese [J].

Higuchi, T ;

Seki, N ;

Kamizono, S ;

Yamada, A ;

Kimura, A ;

Kato, H ;

Itoh, K .

TISSUE ANTIGENS, 1998, 51 (06) :605-612

← 1 2 3 →